中华医学杂志（英文版）2007，Vol.120Issue(9)：771-776,6.
Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro
Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro
SUN Yu 1LI Hui 1WANG Ke-xin 1CHEN Li 1HOU Xin-guo 1HOU Wei-kai 1DONG Jian-jun 1SUN Lei 1TANG Kuan-xiao 1WANG Bin 2SONG Jun1
作者信息
- 1. Department of Endocrinology, Qilu Hospital, Shandong University,Jinan 250012, China
- 2. Yuhuangding Hospital, Yantai 264000, China
- 折叠
摘要
Abstract
Bckground Stem cells, which have the ability to differentiate into insulin-producing cells (IPCs), would provide a potentially unlimited source of islet cells for transplantation and alleviate the major limitations of availability and allogeneic rejection. Therefore, the utilization of stem cells is becoming the most promising therapy for diabetes mellitus (DM). Here,we studied the differentiation capacity of the diabetic patient's bone marrow-derived mesenchymal stem cells (MSCs) and tested the feasibility of using MSCs for β-cell replacement.Methods Bone marrow-derived MSCs were obtained from 10 DM patients (5 type 1 DM and 5 type 2 DM) and induced to IPCs under a three-stage protocol. Representative cell surface antigen expression profiles of MSCs were analysed by flow cytometric analysis. Reverse transcription-polymerase chain reaction (RT-PCR) was performed to detect multiple genes related to pancreatic β-cell development and function. The identity of the IPCs was illustrated by the analysis of morphology, ditizone staining and immunocytochemistry. Release of insulin by these cells was confirmed by immunoradioassay.Results Flow cytometric analysis of MSCs at passage 3 showed that these cells expressed high levels of CD29 (98.28%), CD44 (99.56%) and CD106 (98.34%). Typical islet-like cell clusters were observed at the end of the protocol (18 days). Ditizone staining and immunohistochemistry for insulin were both positive. These differentiated cells at stage 2 (10 days) expressed nestin, pancreatic duodenal homeobox-1 (PDX-1), Neurogenin3, Pax4, insulin, glucagon, but at stage 3 (18 days) we observed the high expression of PDX-1, insulin, glucagon. Insulin was secreted by these cells in response to different concentrations of glucose stimulation in a regulated manner (P＜0.05).Conclusions Bone marrow-derived MSCs from DM patients can differentiate into functional IPCs under certain conditions in vitro. Using diabetic patient's own bone marrow-derived MSCs as a source of autologous IPCs for β-cell replacement would be feasible.关键词
diabetes mellitus/mesenchymal stem cells/insulin/transdifferentiationKey words
diabetes mellitus/mesenchymal stem cells/insulin/transdifferentiation分类
医药卫生引用本文复制引用
SUN Yu,LI Hui,WANG Ke-xin,CHEN Li,HOU Xin-guo,HOU Wei-kai,DONG Jian-jun,SUN Lei,TANG Kuan-xiao,WANG Bin,SONG Jun..Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro[J].中华医学杂志（英文版）,2007,120(9):771-776,6.
